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Summary The expression of p53 protein, epidermal growth factor receptor (EGFR), and Ki-67 nuclear
antigen was examined by immunohistochemistry in biopsies of 16 types of human brain tumours, including 43
astrocytomas. P53 protein, almost certainly its mutant form, was expressed in seven of the 16, and EGFR in
11 of the 16 types of tumours. In astrocytomas both the proportion of tumours which expressed p53 or EGFR increased with grade of malignancy as did the mean Ki-67 labelleing index (LI): p53-0% in grade 1, 17% in
grade 2, 38% in grade 3, 65% in grade 4; EGFR-0% in grade 1, 33% in grade 2, 85% in grade 3, 95% in grade 4; mean Ki-67 Ll- 1.1% in grades 1 and 2, 8.3% in grade 3, and 13.4% in grade 4. Astrocytomas which
expressed p53 or EGFR had a significantly higher Ki-67 LI at P<0.05 (11.8% and 10.7%, resp.) than those that did not (6.2% or 4.1%, resp.). Patients with astrocytomas expressing p53 or EGFR had a significantly reduced survival (P = 0.035 and P = 0.007, resp.): only 11% of the p53 +ve and 13% of the EGFR +ve
patients were alive at 100 weeks following diagnosis compared to 36% of p53-ve or 60% of EGFR-ve patients. Patients with Ki-67 LI >5% had a reduced survival (P< 0.0001) - none survived beyond 86 weeks following
diagnosis, whilst 63% ofpatients with < 5% positive cells were still alive at 100 weeks. The univariate analysis showed that in astrocytomas expression of p53 mutants, EGFR protein, and Ki-67> 5% are associated with malignant progression and poor prognosis. The multivariate analysis revealed that only tumour grade and
Ki-67LI were independent prognostic factors for survival.
Glial tumours are the most common primary tumours of the
CNS (Russell & Rubinstein, 1989). Almost all types of glial
tumours can recur and display malignant progression to
some degree depending on the histopathological type of
tumour, grade of malignancy, its location, the patient's age,
and the extent of surgical resection (Russell & Rubinstein,
1989). However, the onset of the malignant process is highly
variable, and prognostic predictions cannot be made in indi-
vidual patients. In both low and high grade astrocytomas
loss of heterozygosity for alleles on chromosome 17p has
recently been found, suggesting that during early stages of
tumorigenesis mutation and acquisition of homozygosity has
occurred in a recessive oncogene on that chromosome (James
et al., 1989; El-Azouzi et al., 1989). Also, several high grade
astrocytomas have been found to contain point mutations in
gene p53, which is localised on chromosome 17p (Nigro et
al., 1989). Malignant gliomas have also been shown to have
abnormai chromosomes 1, 6, 9, 10, 13, 22, sex chromosomes,
and an extra chromosome 7 (Bigner et al., 1984; James et al.,
1988). The epidermal growth factor receptor (EGFR) gene
which is located on chromosome 7 (Shimizu et al., 1985) has
been shown to be amplified and rearranged (Liberman et al.,
1984; Liberman et al., 1985; Wong et al., 1987; Sugawa et al.,
1990), and the EGFR protein found overexpressed in the
most malignant gliomas, especially the glioblastoma mul-
tiforme (Arita et al., 1989; Reifenberger et al., 1989. On the
basis of these findings Bigner and Vogelstein (1990) have
proposed a model for malignant progression of gliomas in
which losses of chromosomes 17p, 13, or 22 occur in low
grade gliomas, and loss of chromosome 10 represents a
critical step in transition from grade 3 (anaplastic astro-
cytomas) to grade 4 (glioblastoma multiforme), whilst abnor-
malities of 9p and EGFR amplification stimulate further
progression. In Primitive Neuroectodermal Tumours (PNETs)
chromosomes 1 and 17 have been implicated in tumour
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development by cytogenetic studies (Bigner et al., 1988;
Griffin et al., 1988), and subsequently allele loss has been
found on chromosomes 17p, 6q, and 16q (Thomas & Raffel,
1991). The genes affected by putative mutations on these
chromosomes have not yet been identified in PNETs but gene
p53 on chromosome 17p is a candidate.
Normal p53 gene behaves as a tumour suppressor gene. It
encodes a 53kD nuclear phosphoprotein, which is thought to
be involved in regulation of cell growth (Finlay et al., 1989;
Stanbridge, 1990). The normal p53 protein is undetectable by
standard immunohistochemistry because of its low cellular
levels and a very short half-life, about 20 min (Finlay et al.,
1989). Point mutations in the gene lead to expression of
nonfunctional mutant forms with substantially longer half-
lives (up to about 24h), and an elevation of cellular levels to
10-100 fold above normal values (Finlay et al., 1989) which
can be detected by immunohistochemistry (Cattoretti et al.,
1988; Iggo et al., 1990; Rodrigues et al., 1990). An associa-
tion between expression of p53 mutants, epidermal growth
factor receptor (EGFR), and poor prognosis has recently been reported to occur in human breast carcinomas (Harris
et al., 1990) but has not yet been examined in astrocytomas. EGFR is a 170 kD transmembrane glycoprotein with an
extracellular ligand-binding domain, a transmembrane region and an intracellular portion with tyrosine kinase activity (Hunter, 1984). Binding of EGFR or transforming growth factor alfa (TGF-m) to EGFR results in activation oftyrosine kinase activity and stimulation of DNA synthesis, leading to
mitosis (Stoscheck & King, 1986; Carpenter, 1987). The aim of this study was to increase our understanding of
basic biological mechanisms in central nervous system (CNS)
tumours and to correlate expression of mutant p53 protein
and EGFR with tumour proliferative activity and the pa- tients' progress. 78 CNS tumours were examined, including
43 astrocytomas and 6 PNETs using immunohistochemistry
and monoclonal antibodies to p53 and EGFR proteins.
Monoclonal antibodies to the growth fraction-associated Ki-
67 antigen (Gerdes et al., 1984) have been used to assess the
proliferative activity of tumour cells as the Ki-67 labelling
index (LI) has been shown to correlate with the degree of
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malignancy in different types of tumours, including gliomas
(Zuber et al., 1988; Raghavan et al., 1990). Preliminary
results of this study have been presented in part to the British
Neurooncology Society (Jaros et al., 1991a) and to the
British Neuropathological Society (Jaros et al., 1991b).
Materials and methods
Fresh specimens of 78 CNS tumours were obtained during
neurosurgery in Newcastle General Hospital between April
1988 and May 1990. They were divided into several portions:
(i) used for karyotyping employing methods developed for
solid tumours (Adam et al., in preparation);- (ii) fixed in
formalin, embedded in paraffin, and sections stained with
haematoxylin and eosin for histopathological assessment (iii)
snap-frozen in arcton pre-cooled with liquid nitrogen and
stored at - 70'C for immunohistochemistry. Histopatho-
logical assessment of the tumours was made according to the
WHO classification system (Rorke et al., 1985), and the
degree of malignancy was graded according to Kernohan's
system (Kernohan et al., 1949).
Frozen sections of the tumours were cut at 6Itm, mounted
on silanized glass slides and allowed to dry overnight. The
sections were fixed in 1:1 mixture of chloroform:acetone for
10 min at room temperature, dried for 10 min, and incubated
with mouse monoclonal antibodies to human p53 (PAb 1801
from Cambridge Research Biochemicals) at a 1:1600 dilution
(titred to detect p53 protein expressed in control human lung
carcinoma material); or a mouse monoclonal Ki-67 anti-
bodies (Dako) at a 1:25 dilution; or with mouse monoclonal
antibodies to EGFR (EGFR1 from Amersham) at a 1:50
dilution (titred on normal human skin), followed by biotiny-
lated anti-mouse antibodies (Vectastain) at a 1:200 dilution,
streptavidin-biotin-HRP (Amersham) at a 1:100 dilution,
DAB at 0.5 mg ml-I and counterstained with haematoxylin.
All the dilutions of antibodies were prepared in Tris-buffered
saline, pH 7.6, containing 1.5% normal preimmune horse
serum. As a control for endogenous peroxidase the primary
antibodies were omitted on serial sections from each block.
Another serial section was stained with haematoxylin and
eosin for histopathology.
Immunohistochemically processed sections from all the
tumours were examined and those containing nuclei labelled
with the p53 or the Ki-67 antibody were classed as p53 + ve
(p53 positive) or Ki-67 + ve tumours, and were quantified on
a Nikon microscope at x 400 magnification using a square
graticule. When regional heterogeneity of labelling was detec-
ted in the tumour, counting areas were chosen to include
areas with high and low density of p53 positive cells and also
areas in which serial sections showed variation in the Ki-67
or the EGFR labelling. In each area between 901 and and
1566 tumour cells were-counted from systematically ran-
domised fields. Endothelial cells were not included in the
counts, even when in some of the tumours they were labelled
with Ki-67 (though never with the p53) antibody. The p53 or
Ki-67 LI was calculated as a percentage of labelled tumour
cells out of the total number of tumour cells counted (LI =
100 x number of labelled nuclei - total number of nuclei).
The highest Ki-67 LI detected in individual tumours was
considered to represent the proliferative potential within the
tumour (Raghavan et al., 1990), and was therefore used in
quantitative analysis. Because the EGFR labelling of
tumours varied both in terms of cellular intensity and the
proportion of tumour labelled, calculating a simple EGFR
LI may have been inadequate. Instead, for each tumour the
labelling intensity was scored on a scale from - to
+ + + +, and the percentage of EGFR reactive tumour
cells was calculated using an eyepiece with squared graticule.
EGFR labelling factor was then calculated for each tumour
by multiplying percentage of the labelled area by 1 if the
labelling intensity was scored as - (negative), and by 2,3,4,
or 5, respectively, if the labelling intensity was scored as +,
+ +, + + + or + + + +. Student t-test was used to
analyse p53, EGFR or Ki-67 labelling as continuous vari-
ables in relation to tumour grade, and to analyse Ki-67
labelling in relation to p53 or EGFR labelling as categorised
variables. Pearson's correlation coefficient (r) was used to
determine the strength of association between the continuous
variables Ki-67 LI, p53 LI, EGFR labelling factor, and
patient's age.
The prognostic importance of each of the variables with
natural categorisation, i.e. sex, histological grade (1, 2 vs 3,
4), p53 (+ ve vs -ve), EGFR (+ve vs -ve), extent of
surgery (total, subtotal, partial, biopsy), radiotherapy (Y/N),
and chemotherapy (Y/N) was assessed using Log-Rank test
(Peto et al., 1977). The continuous variables, i.e. age and
Ki-67 LI were separately entered into the Cox regression
model (Cox, 1972) to yield relative risks and P-values. This
avoids the need of possibly 'data-driven' categorisation ofthe
variables although Ki-67 was also considered in the form of
<5% vs >5% and analysed using the Log-Rank test. All
variables apart from sex, radiotherapy, and chemotherapy
were entered into the multivariate analysis. The multivariate
analysis was performed by using a forward stepwise applica-
tion of Cox's Regression model via the BMDP statistical
package (Program 2). Variables selected as statistically signi-
ficant by this procedure had P<0.10. 95% confidence inter-
vals for the relative risks in the multivariate procedure are
given by ecoeff± 1.96SE(coef).
Results
Clinical histopathological data
These data are summarised in columns 1-5, and 10-13 of
Table I. Only the astrocytoma group was sufficiently large to
make the Log-Rank test of survival possible. The range of
follow-up time was 0-180 weeks (median= 39 weeks). All
except one of the patients who are still alive (patient number
276) have reached the 100 weeks follow-up (Table I). Out of
the total of 43 astrocytoma patients, three patients who died
of other causes were not included in the Log-Rank analysis.
The length of patient's survival was significantly related to
their age at diagnosis (younger patients showing longer sur-
vival: P = 0.0002; Table II), and to the histopathological
grade of their tumour (P<0.0001; Table III and Figure 1).
In Figure 1 note that patients with malignant grades had a
significantly reduced survival time - only 6% of patients with
grade 3 and 4 were alive at 100 weeks following diagnosis
compared to 89% of patients with grade 1 and 2 tumours.
Sex of the astrocytoma patients, radiotherapy, chemotherapy
or surgery did not significantly affect their survival (Table
III), though surgery was weakly significant (P= 0.06).
Cytogenetic data
These data are shown in column 9 of Table I. Cytogenetic
analysis was performed on short-term cultures of 74% of the
tumours; 50% of the tumours were successfully karyotyped.
Chromosomal abnormalities were found in 21% of all the
tumours: in 13 astrocytomas grade 3 and 4, one angioglioma
grade 4, one malignant choroid plexus papilloma, and one
metastatic melanoma. In the astrocytomas and the angio-
glioma the most common abnormality was aneuploidy of sex
chromosomes, in particular loss of chromosome Y. Trisomy
of chromosome 7, where EGFR gene is known to be
localised, was found in one astrocytoma only (patient No.
113). None of the patients were found to have gross rear-
rangements or deletions of chromosome 17p, where p53 gene
is localised.
Immunohistochemistry ofp53
No labelling was detected in normal neocortical (12 cases)
and normal cerebellar (four cases) tissue adjacent to the
tumours. The p53 labelling of tumours was restricted to the
tumour cell nuclei. No cytoplasmic labelling was observed,
and no endothelial cells were labelled, even in areas showingP53 PROTEIN, EGFR AND KI-67 ANTIGEN IN BRAIN TUMOURS 375
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Table II Univariate analysis (Cox's regression) for age and Ki-67 LI
data
Variable Coefficient SE Relative risk P-value
Age 0.0378 0.0106 1.038 0.0002
Ki-67 LI 0.077 0.021 1.08 0.0001
Table III Univariate analysis (Log-rank test)
Variable X2k P-Value
Sex (F vs M) 0.07 0.79
p53 (+ VE vs -VE) 4.44 0.035
EGFR (+ VE vs -VE) 7.34 0.007
Ki-67 LI (<5% vs >5%) 20.50 <0.0001
Surgery (total vs subtotal vs 7.37 = X23a 0.06
partial vs biopsy)
Histopathology grade (1,2 vs 3,4) 18.30 <0.0001
Radiotherapy (+ vs -) 0.62 0.43
Chemotherapy (+ vs-) 0.01 0.94
aNote, 3 degrees offreedom.
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Figure 1 Survival curves for patients with astrocytomas grade 1
and 2 (-; n = 9) and patients with astrocytoma grade 3 and 4
(---; n = 31). Log-Rank statistic = 18.30; P<0.0001; d.f. = 1.
endothelial proliferation. The nuclear labelling did not cor-
relate with any particular tumour cell type. This was most
obvious in such morphologically heterogeneous tumours such
as glioblastoma multiforme or gigantocellular glioma where
both small and large nuclei were either labelled or unlabelled
(Figures 2 and 3). The intensity of the nuclear labelling
within the tumour also varied: lesser or more intensely
labelled nuclei were intermingled in an irregular fashion
(Figures 2 and 3).
Tumour cell nuclei positively labelled with the p53 anti-
body were found in seven out of 16 types of tumours
examined (Table IV, columns 1 and 2). In astrocytomas it
should be noted that none of the grade 1 tumours were
labelled but that the proportion of positive tumours in-
creased with tumour grade (Table IV, column 3). P53 LI was
variable within astrocytoma grades ranging from 1.2% to
29.4% in grade 3, and from 0.1% to 61.9% in grade 4 (Table
I, column 6), and the mean LI was similar in the two grades
(P = 0.83; Table V) indicating absence ofcorrelation between
p53 LI and the tumour grade, at least for the two malignant
grades. In some tumours a striking regional heterogeneity in
p53 +ve nuclei was evident in histological sections. For
example, in a p53 + ve PNET (patient number 71) shown in
Figure 4, p53 LI in two neighbouring areas was 0.1% and
21.8%. Several astrocytomas grade 3 and 4 also showed
regional heterogeneity in the p53 labelling, the greatest
differences in p53 LI was 1.2% and 22% in patient number
147 (Table I, column 6).P53 PROTEIN, EGFR AND KI-67 ANTIGEN IN BRAIN TUMOURS 379
Table V p53, EGFR, and Ki-67 labelling
histopathological tumour grade
in relation to
pS3 LI EGFR labellingfactor Ki-67 LI
Grade Mean (s.d.;n) Mean (s.d.;n) Mean (s.d.;n)
1 & 2 110.1(31.6;10) 1.1(1.0;10)
vs 3 & 4: P<0.0001 vs 3: P= 0.01
d.f.=41 d.f.=21
3 14.1 (12.2;13) 247.6(113.1;13) 8.3(9.1;13)
vs 4: P=0.83 vs 4: P = 0.1 vs4: P = 0.006
d.f. =31 d.f. = 31 d.f. = 31
4 12.4(16.3;20) 323.0(136.1;20) 13.4(7.3;20)
3 & 4 293.1(131.2;33)
Figure 2 Positive p53 mutant protein nuclear labelling in ast-
rocytoma grade 4 (glioblastoma multiforme) with PAb 1801; both
small and large nuclei were either labelled (brown) or unlabelled
(blue). Scale bar = 30jim.
Figure 3 Positive p53 mutant protein nuclear labelling in gigan-
tocellular glioma with PAb 1801; both small and large nuclei
were either labelled (brown) or unlabelled (blue). Scale
bar = 30jLm.
Table IV Expression of p53 and EGF receptor proteins in CNS
tumours
1
Tumour type
Astrocytoma Grade 1
Grade 2
Grade 3
Grade 4a
Total
Primitive neuro-ectodermal tumours
Astroblastoma
Gigantocellular glioma
Oligodendroglioma
Ependymoma Grade 2/3
Myxopapillary
Angioglioma
Choroid plexus papilloma
CNS dysgerminoma
Pituitary tumour
Haemangioblastoma
Chordoma
Tumours in Von Recklinghausen's
neurofibromab
neurofibrosarcomac
Angioma (developmental abnormality)
Metastatic tumours in CNS
carcinoma
melanoma
2 3
p53 + ve
Ratio %
0/4 0%
1/6 17%
5/13 38%
13/20 65%
19/43 44%
1/6 17%
1/2
1/1
0/1
0/2
0/2
0/3
0/3
2/2
0/3
0/3
0/1
0/1
1/1
0/1
0/2
1/1
4 5
EGFR + ve
Ratio %
0/4 0%
2/6 33%
11/13 85%
9/20 95%
32/43 74%
4/6 67%
2/2
1/1
1/1
2/2
0/2
1/2
3/3
1/2
0/3
2/3
0/1
1/1
1/1
0/1
0/1
0/1
Figure 4 Regional heterogeneity of positive p53 mutant protein
nuclear labelling (brown) with PAb 1801 in primitive neuroec-
todermal tumour: in an area partly shown in the upper half of
the figure p53 LI was 21.8%, in a neighbouring area, partly
shown in the lower half of the figure, p53 LI was 0.1%. Ki-67 LI
quantified from a serial section, was similar in the two areas,
about 9%. Scale bar = 30jim.
Patients with p53 + ve astrocytomas had a reduced sur-
vival (P = 0.035; Table III) - only 11% of these patients were
alive at 100 weeks following operation and diagnosis com-
pared to 36% of patients with p53-ve tumours (Figure 5).
The number of cases with tumours in the other categories
were too small to attempt survival analyses.
Immunohistochemistry ofEGFR
No labelling was seen in normal neocortical (12 x ) and
normal cerebellar (4 x ) nervous tissue adjacent to tumours
or in tumour endothelial cells. The EGFR labelling of
tumours was restricted to cytoplasmic regions and, in some
instances, possibly to cell membranes of tumour cells in the
EGFR + ve tumours (Figures 6 and 7). This is in contrast to
normal human epidermis, which was used to determine the
optimal dilution of the EGFR antibody, where the labelling
was associated exclusively with cell membranes.
Eleven out of 16 types of tumours examined had EGFR
positive cells (Table IV, column 1 and 4). It should be noted
that a higher proportion of all astrocytomas was labelled
with EGFR (74%) than p53 antibody but that, similar to p53 labelling, none of the grade 1 tumours were labelled, and the
proportion of positive tumours increased with tumour grade (Table IV, column 5). In some tumours the EGFR labelling
was intense and uniform both in terms of distribution and
intensity (Figure 6) but in other tumours it was fainter
(Figure 7) or patchy and of variable intensity (see also Table
I, column 7). The variability of these two parameters was
taken into account by calculating EGFR labelling factor for
each tumour (see Material and methods). Astrocytomas
grades 3 & 4 had a significantly higher mean labelling factor
than grades 1 and 2 (P<0.0001; Table V) indicating that the
intensity/area of EGFR labelling increased with malignancy
aIncludes glioblastoma multiforme. bAssociated with spinal roots. clntrinsic to cerebrum.380 E. JAROS et al.
grade. Other tumours with high degree of EGFR labelling
included PNETs, astroblastomas, oligodendrogliomas, chor-
oid plexus papillomas, and angiogliomas (Table I, column 7).
Patients with EGFR + ve astrocytomas appeared to have
reduced survival (P = 0.007; Table III) - only 13% of these
patients were alive at 100 weeks following diagnosis com-
pared to 60% of EGFR-ve patients (Figure 8). The number
of cases with tumours in the other categories were too small
to attempt survival analysis.
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Figure 5 Survival curves for patients with p53 negative astro-
cytomas (p53neg-; n = 22) and patients with p53 positive astro
cytomas (p53pos---; n = 18). Log-Rank statistic = 4.44; P = 0.035;
d.f. = 1.
Immunohistochemistry ofKi-67
At the cellular level the Ki-67 antibody reactivity had an
exclusively nuclear distribution, and was either uniform or
granular (Figure 9). Most tumours had at least some Ki-67
labelled nuclei with the exception of one grade 2 astrocytoma
in tuberous sclerosis, one angioglioma, one chordoma and
and one angioma (Table I, column 8). Heterogeneity in Ki-67
nuclear labelling was found in around of 20% astrocytomas
(Table I, column 8). However, the mean values of the Ki-67,
LI, representing the proliferative potential of the tumour (see
Material and methods), showed a statistically significant in-
crease with increasing grade of astrocytoma malignancy (1
and 2 vs 3; P= 0.01; 3 vs 4: P= 0.006; Table V).
In the Univariate analysis the astrocytoma patients' Ki-67
LI, -when 'analysed as a continuous variable by Cox regres-
sion analysis, showed a strong relationship to the length of
surival (P>0.0001; Table II). When analysed by the Log-
Rank test patients with Ki-67 LI> 5% (5.1 to 30.9%) had a
reduced survival (P<0.0001; Table III) - none of these
patients survived beyond 86 weeks following diagnosis com-
pared with 63% of patients with Ki-67 LI of <5% (0.1 to
3.9%) who were still alive at 100 weeks (Figure 10). The
number of cases with tumours in the other categories were
too small to attempt survival analysis.
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Figure 6 Intense positive EGFR labelling (brown) in ast-
rocytoma grade 4 (glioblastoma multiforme) with EGFRI
antibody; the blood vessel (v) is unlabelled. Scale bar = 30jim.
0 10 20 30 40 50 60 70 80 90 100
Time (weeks)
Figure 8 Survival curves for patients with EGF receptor nega-
tive astrocytomas (EGFRneg-; n = 10) and patients with EGF
receptor positive astrocytomas (EGFRpos---; n = 30). Log-Rank
statistic = 7.34; P = 0.007; d.f. = 1.
Figure 7 Faint EGFR labelling (pale brown) in gigantocellular
glioma with EGFR1 antibody. Scale bar= 301tm.
Figure 9 Positive Ki-67 nuclear labelling (brown) in astrocytoma
grade 4 (glioblastoma multiforme); a blood vessel (v) displays one
labelled endothelial cell nucleus (arrow). Scale bar = 30l,m.
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Figure 10 Survival curves for patients with Ki-67 LI below 5%
(<5%-; n= 16) and patients with Ki-67 LI above 5% (>5%
---n = 24). Log-Rank statistic = 20.50; P<0.0001; d.f. = 1.
Relationship between p53, EGFR and Ki-67 labelling
In about 25% of the astrocytomas regional heterogeneity was
detected either in p53, EGFR, or Ki-67 labelling, and
therefore more than one area was counted in those tumours
(Table I, columns 6, 7, 8). Note that in most cases only one
of the three antibodies showed heterogeneity, in a few cases
two antibodies but never all three simultaneously. The rela-
tionship between p53, EGFR and Ki-67 labelling was deter-
mined in serial sections from corresponding areas but not
between different areas. The p53 + ve astrocytomas had a
significantly higher mean Ki-67 LI than p53-ve astrocytoma
(P = 0.036; Table VI), although the values of the continuous
variables, p53 LI and Ki-67 LI, did not show any correlation
within the individual tumours (r = 0.19; P = 0.17). A pic-
torial example of absence of correlation should be noted in
Figure 4 where regional heterogeneity in the p53 labelling
cannot be explained by differences in proliferative activity
between the two areas since they both had an almost iden-
tical Ki-67 LI of 9%.
The continuous variables, EGFR labelling factor and Ki-
67 LI, were significantly correlated within the individual
tumours (r = 0.32; P = 0.018). The EGFR + ve astrocytomas
had a significantly higher mean Ki-67 LI than EGFR-ve
astrocytomas (P = 0.028; Table VI). Astrocytomas which
were both EGFR + ve and p53 + ve had a somewhat higher
Ki-67 LI than astrocytomas which were EGFR +ve but
p53-ve, though the difference was not significant (P = 0.49;
Table VI). Astrocytomas not expressing either EGFR or p53
proteins had the lowest mean Ki-67 LI (P<0.0001; Table
VI), although the continuous variables, p53 LI and EGFR
labelling factor, showed no correlation within individual
tumours (r = 0.04; P = 0.86). The absence of correlation is
probably due to variability in p53 LI between tumours (see
Table I, column 6), and also due to non-overlapping regional
heterogeneity in EGFR and p53 labelling within individual
tumours.
The effect of EGFR and p53 expression on patient's sur-
vival was not cumulative (P = 0.66; Figure 11) - similar
proportions ofpatients with EGFR + ve & p53 + ve tumours
(12%) were alive at 100 weeks following diagnosis compared
to patients with EGFR +ve & p53-ve tumours (15%). In
contrast, patients with EGFR-ve & p53-ve tumours had a
significantly better survival rate than both of the previous
groups (67%; P = 0.016; Figure 11).
Multivariate analysis
The list of all variables which were analysed for prognostic
importance by univariate analysis are shown in Table II
(Cox's Regression for continuous variables) and in Table III
(Log-Rank test for categorised variables). Note that the
univariate prognostic importance of Ki-67 LI is of the same
order of magnitude (P<0.0001) whether it is considered as a
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Figure 11 Survival curves for patients with p53 negative and
EGFR negative astrocytomas (EGFRneg and p53pos-; n=9),
patients with p53 negative and EGFR positive astrocytomas
(EGFRpos and p53neg ---; n = 13), and patients with p53 pos-
itive and EGFR positive astrocytomas (EGFRpos and p53pos
. .; n = 17). Log-Rank statistic = 8.29; P = 0.016; d.f. = 2. The
only patient with a p53 positive and EGFR negative astrocytoma
died 24 weeks after diagnosis. For EGFRpos and p53neg vs
EGFRpos & p53pos survival curves the Log-Rank statistic=
0.19; P = 0.66; d.f. = 1.
Table VI Ki-67 labelling in relation to p53 and EGFR labelling
Ki-67 LI Degrees of
Mean (SD;n) P-value freedom
p53-ve 6.2(6.6;24)
vs 0.036 41
p53 + ve 11.8(10.2;19)
EGFR-ve 4.1(6.3;11)
vs 0.028 41
EGFR + ve 10.7(8.8;32)
p53-ve & EGFR + ve 9.0(7.3;14)
vs 0.49 30
p53 + ve & EGFR + ve 11.2(10.2;18)
p53-ve & EGFR-ve 2.3(2.7;10)
vs <0.0001 40
EGFR + ve (= p53-ve & EGFR + ve 10.7(8.8;32)
plus
p53 + ve & EGFR + ve)
p53 + ve & EGFR-ve 21.6 (1)
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continuous or categorical (<5% vs >5%) variable. Sex,
radiotherapy and chemotherapy had non-significant uni-
variate P-values, while surgery was of weak statistical impor-
tance (P = 0.06; Table III). All variables apart from sex,
radiotherapy and chemotherapy were entered into a mul-
tivariate analysis to determine whether they influence the
patient's prognosis independently or are associated with each
other. The multivariate analysis was performed by using a
forward stepwise application of Cox's Regression model.
Tables VII and VIII shows that the only variables selected as
statistically significant (P<0.10) by this procedure were his-
topathological grade and Ki-67 LI. Although several of the
variables had a significant prognostic importance following
univariate analysis (Tables II and III), the multivariate
analysis reveals histopathological grade as the overwhelming
dominating factor with Ki-67 LI being the only other var-
iable with prognostic information once histopathological
grade has entered the model. By employing the regression
procedure with only Ki-67, EGFR and p53 labelling as
independent variables, only Ki-67 labelling was significant
(P = 0.0002), and therefore the controlling variable. This is
because many of the variables do not influence the survival
of astrocytoma patients independently, and are interrelated
with each other as follows, histopathological grade and age:
1 and 2 vs 3 and 4; P<0.0001; histopathological grade and
Ki-67 LI: 1 and 2 vs 3: P=0.01, 3 vs 4; P=0.006; his-
topathological grade and EGFR labelling factor: 1 and 2 vs 3
and 4: P<0.0001; age and Ki-67 LI: r = 0.37, P = 0.014; age
and EGFR labelling factor: r=0.57, P<0.0001; Ki-67 LI
and EGFR labelling factor: r = 0.32, P = 0.018; except for
histopathological grade and p53 LI: P = 0.83; age and p53
LI: r = 0.06, P = 0.77; Ki-67 LI and p53 LI: r = 0.19,
P = 0.17; and EGFR labelling factor and p53 LI: r = 0.04,
P = 0.86.
Discussion
This study demonstrates immunohistochemically detectable
levels of p53 protein in tumour cell nuclei of many CNS and
non-CNS tumours. The PAb 1801 monoclonal antibody used
in this study can recognize both normal and mutant forms of
human p53 proteins (Banks et al., 1986; Rodrigues et al.,
1990) but the labelling almost certainly represents accumula-
tion of nonfunctional p53 mutants only. The mutants are
detectable by immunohistochemistry (Cattoretti et al., 1988;
Iggo et al., 1990; Rodrigues et al., 1990) because of their
metabolic stability, and their cellular levels are elevated
10-100 fold above normal values (Finlay et al., 1989). In the
present series none of the normal CNS tissue adjacent to the
tumours was labelled with PAb 1801 antibody. Also, the
labelling of tumour cells is unlikely to represent the some-
what elevated levels of normal p53 seen in actively pro-
liferating cell populations (Dippold et al., 1981; Levin &
Momand, 1990) because some tumours with large growth
fractions were not labelled with the PAb 1801 antibody,
whilst in p53 + ve tumours the p53 LI did not correlate with
the growth fraction size. In addition, no endothelial cells
were labelled in any of the tumours, even in areas where
endothelial proliferation, and Ki-67 labelling were present.
Our finding that p53 mutants are expressed in astrocy-
tomas, primitive neuroectodermal tumour, astroblastomas,
gigantocellular glioma, neurofibrosarcoma, CNS dysgermino-
mas, and melanoma extends the number of human tumours
with identified mutations in p53 gene. So far, the list included
carcinomas of the breast, lung, colorectum, and liver, and
also neurofibrosarcoma, osteosarcoma and glioblastomas
multiforme (Masuda et al., 1987; Cattoretti et al., 1988;
Nigro et al., 1989; Iggo et al., 1990; Rodrigues et al., 1990;
Menon et al., 1990; Bressac et al., 1991; Hsu et al., 1991).
Using karyotyping we have not detected abnormalities of
chromosome 17p (where gene p53 is localised) in any of the
p53 + ve tumours in this study. This may not be surprising
since accumulation of p53 protein is almost certainly an
outcome of point mutations in the p53 gene (Nigro et al.,
1989) which is beyond resolution of karyotyping.
In the present series the p53 labelling was exclusively
localised in tumour cell nuclei, whilst in other tumour types
either nuclear or a combined nuclear and cytoplasmic p53
labelling has been found (Iggo et al., 1990; Rodrigues et al.,
1990). The nuclear localisation may indicate presence of
transforming p53 mutants. Normal p53 protein is thought to
have a role in regulating gene expression or DNA replication
(Michalovitz et al., 1991), and it appears that nuclear
localisation of p53 mutants is essential for their transforming
activity (Shaulsky et al., 1990). The reason for some p53
mutants accumulating in the nuclei is unclear. Cytoplasmic
accumulation of some p53 mutants has been reported to
occur because a conformational change in their molecule
leads them to form complexes with cytoplasmic heat-shock-
cognate protein 70 (hsc 70; Sturtzbecher et al., 1988). It
would be of interest to see whether the p53 mutants that
accumulate in nuclei of different tumour types in this and
other studies share a particular conformational change, and
bind to an as yet unidentified nuclear protein.
In astrocytomas this study has found that the nuclear
Table VII Variables that achieved P <0.10 following forward stepwise
Cox regression on all variables, Ki-67 LI analysed as continuous
variable
X21 to
Relative risk enter
Variable Coefficient SE (95% C.L)a P-value model
Histological 2.920 1.050 18.50 0.005 26.23
grade (2.37,145.2)
Ki-67 LI 0.044 0.025 1.045 0.08 2.99
(0.99,1.10)
'95% C.I. = 95% Confidence Interval for Relative Risk is given by
ecoefficient ± 1.96SE(coefficient)
Table VIII Variables that achieved P <0.10 following forward stepwise
Cox regression on all variables, Ki-67 LI categorical <5% vs>5%
x2 to
Relative risk enter
Variable Coefficient SE (95% C.L)a P-value model
Histological 2.694 1.082 14.80 0.012 26.23
grade (1.78,123.2)
Ki-67 LI 0.975 0.508 1.921 0.055 4.31
(0.98,7.17)
'95% C.I. = 95% Confidence Interval for Relative Risk is given by
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expression of p53 mutants was associated with increase in
tumour malignancy and poor prognosis. Using immunohis-
tochemistry, similar observations, though without survival
data, have been made in neurofibrosarcoma, and carcinomas
of the breast, lung, and colorectum (Baker et al., 1989;
Vogelstein et al., 1989; Iggo et al., 1990; Harris et al., 1990;
Menon et al., 1990). In astrocytomas p53 expression has not
yet been examined by immunohistochemistry but allele loss
of chromosome 17p, and presumed mutations in p53 gene,
have been reported to be associated with tumour initiation
(James et al., 1989; El-Azouzi et al., 1989) which contrasts
with the findings of the present study. The reason for this
apparent difference between conclusions of the present and
previous studies may be due to the difference in sensitivities
of the different techniques employed, and may not emerge
until the mechanism of tumour evolution in astrocytomas is
more precisely understood at molecular level. However,
several possible explanations might be considered. Firstly,
low and high grade astrocytomas may originate from differ-
ent tumour precursor cells (James et al., 1988). The precursor
cells giving rise to low grade astrocytomas may be affected by
loss-of-function p53 mutations leading to a failure to express
any p53 RNA and protein, similar to that reported in a
proportion of rhabdomyosarcomas, osteosarcomas, and Li-
Fraumeni lesions (Masuda et al., 1987; Mulligan et al., 1990;
Malkin et al., 1990). Only precursors giving rise to high
grade astrocytomas may be affected by transforming p53
mutations leading to overexpression of the p53 mutants,
similar to that reported in carcinoma of the breast and lung
(Cattoretti et al., 1988; Iggo et al., 1990). This scheme,
however, implies that benign astrocytomas cannot progress
to a malignant stage, which is contrary to clinical and his-
topathological observations (Russell & Rubinstein, 1989).
Alternatively, if astrocytomas progress from low to higher
grades (James et al., 1988), they may do so by step-wise
changes in the p53 gene, analogous to those proposed for
colorectal carcinomas: the first or initiating step involving
mutation in one allele only and a synthesis of inactive
mutant/normal oligomers; further loss of control is believed
to result from deletion of the normal allele, leaving the cell
with only a mutant allele (Nigro et al., 1989). The present
immunohistochemical essay has detected p53 mutant mole-
cules, but may not have been sufficiently sensitive to detect
cells expressing oligomeric p53 mutant/normal molecules,
similar to observation made by Rodrigues et al. (1990) on
cell lines derived from acute lymphoblastic leukaemia. The
finding that p53 LI was variably expressed between tumours,
and regionally heterogeneous within tumours, indicates that
p53 mutant molecules were expressed in subclones of astro-
cytic tumour cells, which were not present at the initial stages
of tumour development. If a precursor cell expressed p53
mutants, all the daughter tumour cells in high grade astro-
cytomas would also express the mutant molecules.
In this series EGFR was expressed in astrocytomas and ten
other tumour types, mostly with glial and/or neuroepithelial
differentiation, but not in normal brain tissue adjacent to the
tumours. In astrocytomas EGFR expression was associated
with increase in tumour malignancy and poor prognosis. Our
data confirm findings of previous biochemical (Liberman et
al., 1984; 1985) and immunohistochemical studies on astro-
cytomas (Reifenberger et al., 1989), and extend them by
survival data. But, unlike human breast cancer (Harris et al.,
1990), this series does not support a direct association
between expression of EGFR and p53 mutants: there was no
correlation between p53 LI and categories of EGFR label-
ling, possibly due to nonoverlapping regional heterogeneity
in each parameter. This suggests that in astrocytomas p53
mutants and EGFR are expressed in different subclones of
tumour cells, and that the associations between increase in
tumour malignancy and the expression of EGFR protein or
p53 mutants occur independently of each other.
Overexpression of EGFR, previously found to occur in a
high proportion of malignant gliomas, has been related either
amplification of the EGFR gene, often in the form of
double minutes (Liberman et al., 1984; 1985; Wong et al.,
1987), or to an extra copy of chromosome 7 (Liberman et al.,
1984) on which the EGFR gene is located (Shimizu et al.,
1985), or to loss of control of transcriptional activity of the
gene (Gerosa et al., 1989). In this study trisomy of chromo-
some 7 was found only in one patient, and double minutes in
none. It therefore seems that in the present series the possible
mechanisms responsible for EGFR overexpression are either
amplification at the EGFR gene locus which is not easily
detectable by karyotyping, or loss of control of transcrip-
tional activity. Our observation that in the majority of the
brain tumours EGFR labelling had a predominantly cytop-
lasmic distribution may be explained by rapid internalisation
of the EGR after ligand binding (Stoscheck & King, 1986;
Humphrey et al., 1990). Alternatively, similar to human
glioma cell lines which show co-expression of high levels of
EGFR and one of its ligands TGF-a (Nister et al., 1988), an
autocrine growth stimulation loop may operate in astro-
cytomas in vivo, and the cytoplasmic labelling may represent
cytoplasmic binding of EGFR to its ligand.
In this series high Ki-67 LI was associated with reduced
survival. This is contrary to the only previous study which
included survival data (Zuber et al., 1988), possibly due to a
small sample size in the previous study. It is likely that the
poor prognosis found in patients with Ki-67 LI higher than
5% reflects a significant correlation between mean size of the
growth fraction, as determined with the Ki-67 index, and
histopathological grade of malignancy in astrocytomas. The
latter observation is in broad agreement with previous studies
(Raghavan et al., 1990; Brown & Gatter, 1990) but the
conclusions of the present study go further - the Multivariate
analysis has demonstrated that the histopathological grade is
the most important variable to influence the patient's sur-
vival, when all variables are considered together. The analysis
has also demonstrated that histopathological grade, age, Ki-
67 LI, and EGFR and p53 labelling do not influence survival
of astrocytoma patients independently but, except for the p53
labelling, are interrelated with each other. The proliferative
ability of astrocytoma cells, as determined by Ki-67 LI,
appeared to be positively influenced by expression of both
p53 mutants and EGFR protein, since p53 + ve or EGFR
+ve astrocytomas had significantly higher Ki-67 indices
than p53-ve or EGFR-ve astrocytomas but the Ki-67 LI is
the most important variable to influence the patient's survival
when considered together with the EGFR and p53 labelling.
This finding and two other observations indicate that addi-
tional or alternative mechanisms to expression of p53
mutants and EGFR are likely to be involved in controlling
tumour cell proliferation and tumour progression in ast-
rocytomas. Firstly, in p53-ve and/or EGFR-ve astrocytomas
tumour cells also displayed proliferative activity, even though
it was lower than in p53 + ve and/or EGFR + ve tumours.
Secondly, though EGFR labelling correlated positively with
Ki-67 LI, analysis of p53 LI and Ki-67 LI did not show a
significant correlation. These conclusions are in keeping with
earlier cytogenetic findings which have implicated multiple
chromosomal abnormalities in malignant progression of
gliomas in addition to 17p and 7, where p53 and EGFR
genes respectively, are localised (Bigner et al., 1984; Shapiro,
1986; James et al., 1988). In model for progression ofgliomas
Bigner and Vogelstein (1990) proposed that abnormality on
chromosome 17p occurs at early stages of tumorigenesis,
whilst EGFR is thought to stimulate further progression of
malignant gliomas. This study has demonstrated that in ast-
rocytomas expression of both p53 mutants and EGFR can
occur at early stages of tumorigenesis, and that their expres-
sion also represents mechanisms associated with malignant
progression and poor prognosis but that expression of
neither protein may be essential for this process.
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